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Abstract
Background: The acute assessment of patients with suspected ischemic stroke remains challenging. The use of brain
biomarker assays may improve the early diagnosis of ischemic stroke. The main goal of the study was to evaluate whether
the NR2 peptide, a product of the proteolytic degradation of N-methyl-D-aspartate (NMDA) receptors, can differentiate
acute ischemic stroke (IS) from stroke mimics and persons with vascular risk factors/healthy controls. A possible correlation
between biomarker values and lesion sizes was investigated as the secondary objective.
Methods and Findings: A total of 192 patients with suspected stroke who presented within 72 h of symptom onset were
prospectively enrolled. The final diagnosis was determined based on clinical observations and radiological findings.
Additionally gender- and age-matched healthy controls (n = 52) and persons with controlled vascular risk factors (n = 48)
were recruited to compare NR2 peptide levels. Blinded plasma was assayed by rapid magnetic particles (MP) ELISA for NR2
peptide within 30 min and results for different groups compared using univariate and multivariate statistical analyses. There
was a clinical diagnosis of IS in 101 of 192 (53%) and non-stroke in 91 (47%) subjects. The non-stroke group included
presented with acute stroke symptoms who had no stroke (n = 71) and stroke mimics (n = 20). The highest NR2 peptide
elevations where found in patients with IS that peaked at 12 h following symptom onset. When the biomarker cut off was
set at 1.0 ug/L, this resulted in a sensitivity of 92% and a specificity of 96% to detect IS. A moderate correlation (rs = 0.73)
between NR2 peptide values and acute ischemic cortical lesions (,200 mL) was found.
Conclusions: This study suggests that the NR2 peptide may be a brain specific biomarker to diagnose acute IS and may
allow the differentiation of IS from stroke mimics and controls. Additional larger scale clinical validation studies are required.
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Introduction
About 20–30% of all patients admitted to the emergency
department (ED) are having stroke-like symptoms as reported in
hospital based studies [1,2], while more selective criteria [3]
showed that above the age of 50 years, stroke mimics are very rare
(3%). The diagnosis of IS is largely based on clinical assessment
and neuroimaging. However, up to 40% of all acute stroke
patients cannot have an emergent brain MRI [4,5], either because
it is contraindicated or unavailable. Timely and accurate
identification of IS patients is essential for optimal patient triaging
and choice of treatment strategy [6]. A rapid and affordable assay
that can detect brain-borne biomarkers in blood following IS, and
that allows to differentiate IS from non-stroke could potentially
reduce the cost of unnecessary admissions and diagnostic workups.
Currently, a number of biomarkers for stroke diagnosis are
being investigated in clinical studies, including in the emergency
room (ER) and in- and outpatient settings [7]. However, no
biomarker(s) has yet proven to be effective at differentiating IS
from non-stroke. In addition, blood assays detecting brain
biomarkers may enhance the ability to detect acute stroke in the
presence of prior strokes [8].
This study examined the diagnostic potential of the NR2
peptide assay to differentiate acute IS from stroke mimics and
controls when used in conjunction with neurological assessments
and MRI/CT imaging. The secondary objective was to explore a
possible correlation between biomarker values and stroke lesion
volumes in stroke patients presenting within 72 h of symptom
onset.
Methods
This was a prospective, blinded study performed from January
2005 to March 2011 at two clinical sites. The local Investigative
Research Board Committees approved the study, and written
informed consent was obtained from each enrolled subject or a
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family member. Patients with suspected TIA or acute stroke were
admitted to the Emergency Department (ED) at DeKalb Medical
Center (Decatur, GA) and at Ingham Regional Medical Center,
Michigan State University (Lansing, MI). Additionally individuals
with vascular risk factors and healthy controls were recruited at
Penn State College of Medicine (PSU) and Kennesaw State
University (KSU). All controls besides informed consent complet-
ed a standard questionnaire detailing medical history, stroke risk
factors, medication use, and history of any prior strokes.
Subjects
Adults, 18 years or older with suspected TIA (defined as a
neurological deficit that resolved within 24 h), or acute stroke
presenting within 72 h of symptom onset were included in the
study. Patients were excluded if they were pregnant, or had been
transferred from an inpatient care facility.
The study included a total of 460 subjects recruited as a
convenience population: there were n= 360 patients enrolled in to
the stroke study, 52 healthy controls, and 48 individuals with
vascular stroke factors. In the stroke study population 93 patients
were excluded as they did not undergo emergent CT/MRI
imaging due to metal implants, medical instability, obesity or
severe claustrophobia. Patients with intracerebral hemorrhage
(n = 10) and IS patients without known time of symptom onset or
time last known being well (n = 36) were excluded as well. Severely
hemolyzed plasma samples withdrawn from 29 TIA/stroke
patients could not be analyzed reliably and those subjects were
excluded from the study. Data from 292(63%) study participants
have been included in the final analysis of the study (Fig. 1).
Clinical and radiological procedures
All patients who presented with acute stroke symptoms within
the study time window underwent a standard neurological and
general medical evaluation and assessment using the National
Institutes of Health Stroke Scale (NIHSS). Past medical history
and medication history were obtained and a head CT or brain
MRI was performed within 24 h. Each patient was seen and
followed during hospitalization by an experienced stroke neurol-
ogist. Hospital course and discharge examination data were also
noted. History of prior strokes was based upon history,
documented in the medical records, and findings on imaging
studies.
Standard MRI included axial fluid attenuation recovery
(FLAIR), T1- sagittal, T2-weighted axial, diffusion weighted
imaging (DWI), and apparent diffusion coefficient maps that a
board certified neuroradiologist at each site read and interpreted.
Stroke location and ischemic stroke volumes were reported [9],
and then reports were uploaded to each subjects’ file. MRI images
were obtained on a clinical MRI scanner (Siemens 1.5 Tesla
Avanto) operating with single-shot echo planar-capable gradients.
General Electronics (GE, USA) Centricity software was used for
image analysis.
Infarct volumes were measured using computer-assisted volu-
metric software (Analyze software 6.1; Biomedical Imaging
Resource, Rochester, Minn). A pen-trace method was used to
outline the region of interest (i.e., area of acute stroke) on each
axial image and the total volume was reported in mL. In cases of
multifocal infarction, the sum of the individual volumes was used.
Sample collection and storage
This study involved a single blood draw from each recruited
participant after clinical determinations were performed. Blood
samples (5 mL) were drawn by venipuncture into vacuum tubes
containing sodium EDTA (Becton Dickinson) placed on ice.
Plasma drawn from each participant was separated by centrifu-
gation at 3,000 rpm for 5 min at 4uC. Sample processing was
completed within 30 min of blood collection to protect the NR2
peptide from depletion by endogenous serine proteases. Hemo-
lyzed plasma was not acceptable due to cross-reaction with
hemoglobin.
Processed samples were stored as multiple 0.5-mL aliquots
(n = 6) at 280uC before delivery to KSU Lab.
NR2 peptide detection in plasma
Aliquot from each batch of samples (n = 30) was analyzed for
NR2 peptide according to the manufacturer’s manual (Gold Dot
Test, CIS Biotech, Inc., Atlanta, GA) by an investigator blinded to
the clinical and imaging data. Once aliquot was thawed for testing
and used, remaining amounts were discarded.
Briefly, 20 uL plasma samples, five calibrators, negative/
positive controls in duplicates, and 80 uL of working mixture
consisting of magnetic particles (MP) with covalently attached
specific antibodies against NR2 peptide were added to the
microtiter plate. The mixture was incubated for 2 min at 37uC;
Figure 1. Flow diagram of study population: (i) patients with definite acute ischemic stroke (IS) and TIA, (ii) the non-stroke group
included patients presented with acute stroke symptoms and had no stroke and stroke mimics, (iii) control group comprising
healthy volunteers and persons with controlled vascular risk factors (hypertension, diabetes mellitus, and heart disease).
doi:10.1371/journal.pone.0042362.g001
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NR2 antibodies labeled horseradish peroxidase (HRP) solution
was then added for 20 min at 37uC. After the bound magnetic
particles were washed with a buffer using a magnetic separator, the
reaction was revealed by pipetting 100 uL ready-to-use TMB
substrate into each well of a microtiter plate. The color reaction
was developed for 8 min at 25uC, stopped with acid solution
(100 uL), and monitored at 490/630 nm on a microplate reader
(Bio Tek ELx800TM, Fisher Sci.).
The NR2 peptide concentrations in plasma were determined by
plotting their absorbance values on a calibration curve constructed
from the absorbance units of each calibrator and their known
concentrations. Assay results were filed by the Lab director into a
restricted access database. The intra-assay coefficient variation
(CV) was 5.3%–6.3%, and the interassay CV was 5.9%–9.8%.
Statistical analysis
To distinguish between the stroke and non-stroke, definite and
probable strokes (TIA) were classified as stroke, whereas definite
non-stroke and possible strokes (TIA) who had no evidence of
stroke or TIA during the further diagnostic workup were referred
as non-stroke.
Differences between groups were assessed using descriptive
statistics and standard tests of significance. Univariate statistical
analyses with 95% CIs were calculated. Analyses were performed
on the number of subjects included in the study using R Statistical
package (http://www.r-project.org/). Continuous independent
variables were compared by use of the one-way ANOVA followed
by post hoc test. The Spearman rank correlation test was used to
analyze the association between NR2 peptide values and infarct
volume measured on CT or MRI.
A receiver operator characteristic (ROC) curve was used to
calculate the cutoff value for optimal sensitivity and specificity
[10]. ROC curves (sensitivity vs. 1-specificity) for IS vs 3 different
groups (stroke mimics presenting with acute stroke like symptoms
and all controls) by varying the cut off value for distinguishing IS
from non-stroke were built. The gold standard used for
constructing the ROC curve was based on final diagnoses. We
used the partial area under the ROC curve for the region with
specificity between 0.75 and 0.95, as a global measure of the
diagnostic effectiveness of the NR2 peptide assay [11]. To test the
global null hypothesis that the NR2 peptide does not have
adequate accuracy to differentiate IS from non IS, we evaluated if
the average AUC is at least 0.8.
Results
Patients and control group characteristics
We studied 192 patients of 360 subjects included in the study
with suspected acute IS prospectively enrolled at participating
clinical sites within 72 h of symptom onset. Clinical assessments,
diagnostic workup, and imaging confirmed the final diagnosis as
definite stroke in 87(45%), definite TIA in 6(3%), and probable
stroke in 8(4%). A definite non-stroke group comprised 20(10%)
patients with stroke mimics (migraine, seizures, and meningitis)
and 71 (37%) patients who presented with acute stroke symptoms
but had no stroke (history of stroke and TIA .1 year prior to the
study, n= 60, aneurism, n= 8, and palsies, n = 3): 45 (23%) as a
possible stroke, 26 (14%) as a possible TIA (Table 1). The
dichotomized final diagnosis was IS in 101 of 192(53%) and
neurological deficits of other etiology in 91(47%).
Median NIHSS for patients with IS on admission was 5.3
(range, 1–20) with infarct volumes ranging from 1–250 mL. In the
acute IS group, 43% and 57% of patients had cortical and
subcortical strokes, respectively. Two patients admitted to the ED
with TIA progressed to acute IS within 24 h of admission.
The control group included gender- and age-matched healthy
individuals (n = 52) and persons with vascular risk factors (n = 48)
without history of stroke. Characteristics of the study population
subdivided into stroke, non-stroke, and controls are recorded in
Table 1.
NR2 peptide concentrations
The NR2 peptide plasma concentrations for each group are
shown in Fig. 2. There were no adverse events from performing
the NR2 peptide assay. Medication use did not modify biomarker
concentrations.
Ninety three patients with acute cortical and subcortical IS
(definite stroke, n= 81, definite TIA, n= 6, and probable stroke,
n = 6) had an increased NR2 peptide level with a median
concentration of 5.44 ug/L (range, 0.1–62.71 ug/L). There were
patients (n = 8) with acute IS (definite stroke n= 6 and probable
stroke n= 2) and low NR2 peptide-concentrations (0.1–0.93 ug/L)
with four of them having a recurrent stroke within 1–6 months
prior to study enrollment. Healthy individuals had a median value
of 0.33 ug/L (range, 0.02–1.15 ug/L), whereas a median concen-
tration of 0.27 ug/L (range, 0.01–1.54 ug/L) was calculated for
individuals with controlled vascular risk factors. Healthy individ-
uals (n = 2) and persons with controlled vascular risk factors (n = 2)
showed increased NR2 peptide values (1.10–1.54 ug/L).
Group comparison of mean values of the NR2 peptide
concentration demonstrated significant differences (P,0.0001)
for patients with acute IS compared to all control groups.
Analysis of the NR2 peptide distribution in patients with acute
IS depending on the time of symptoms onset is shown in Fig. 2b.
We observed the increased NR2 peptide values (1.46–5.38 ug/L)
in 3 patients with subcortical lesions (about 1 mL size) within 1 h
after the onset. The highest peptide concentrations (median
8.68 ug/L, range 1.20–62.71 ug/L) occurred within 1–12 h
following symptom onset. There was a moderate to strong
correlation (rs = 0.73) between the size of acute ischemic lesions
found on brain CT/MRI and NR2 peptide concentrations in
acute IS patient for cortical lesions measuring ,200 mL (Fig. 2c).
There was no correlation found for the biomarker values and
cortical lesion volumes beyond 200 mL (rs = 0.21).
Operating characteristics of the NR2 peptide are depicted in
Table 2. The predictive values and likelihood ratios at specific
cutoff points were chosen to approximate a sensitivity of 92 and
98% and specificities of 72%, and 96%, respectively. The optimal
cutoff value for acute IS diagnosis was 1.0 ug/L with a sensitivity
of 92% and a specificity of 96% at which a positive predictive
value of 93% for the NR2 peptide assay was achieved.
Considering a prior probability of stroke (odds) of 34%, positive
and negative post-test probabilities resulted in 93% (95% CI, 87%
to 96%) and 4% (95% CI, 2%–8%) respectively.
The tradeoffs between true-positive and false-positive rates are
shown by presenting the data as a traditional ROC curve (Fig. 2d).
The proportional areas under 3 curves (AUC) comparing acute IS
vs healthy control and vascular risk factors (all controls), vs non-
stroke, and vs all controls and non-stroke yielded in close-up values
of 0.914–0.930.
Discussion
The availability of a sensitive biomarker assay has significant
implication for stoke patients. Timely assessment of ischemic
stroke requires attention from multidisciplinary medical specialists
and nurses (primary care, heart and vascular service, anesthesi-
NR2 Peptide Assay for Acute Ischemic Stroke
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ology, and emergency medicine) who are the first to meet patients
suspected of having a stroke. A rapid and accurate assessment of
acute IS in a patient who presents with symptoms suggestive of
transient ischemic attack/stroke to a primary care physician or
nurse/resident or at the ED is imperative for providing the best
possible and most timely care. It is especially needed, when MRI is
contraindicated, as is the case in a number of patients due to metal
implants, medical instability, obesity, and/or severe claustropho-
bia. A biomarker for acute IS may help to diagnose and manage
these patients more safely and effectively [12].
It has been proposed that biomarkers of neurotoxicity and
oxidative stress may be indicative for the assessment of cerebral
ischemia [13]. Recently it was shown that N-methyl-D-aspartate
(NMDA) excitatory receptors which are located on the surface of
microvessels, regulate vasoconstriction/vasodilatation, and subtle
neurovascular dysfunctions [13,14]. The NR2 peptide has also
been recently identified as a plasma biomarker for acute cerebral
ischemia [15]. During the acute phase of the ischemic cascade, a
massive release of glutamate up-regulating excitotoxic NMDA
receptors has been detected [16], in particular, from endothelial
cells of cerebral microvessels [14]. The N-terminal fragments of
the NR2-subunit are rapidly cleaved by serin-proteases and
released into the bloodstream, where they can be detected directly
as NR2 peptide fragments with a molecular weight of about 5 kD
[15].
The diagnostic yield of NR2 peptide measurements in blood
when used in conjunction with a detailed neurological assessment
and radiological evaluation of ischemic stroke patients has been
recently reported as a case report study (see File S1) [17]. To
explore further the NR2 peptide diagnostic potential in bigger size
population, a suitable clinical indication should be considered.
The present study was focused on performance characteristics of
NR2 peptide biomarker assay to differentiate patients with acute
ischemic stroke from all other non-stroke (presented with acute
stroke symptoms but had no stroke, stroke mimics, vascular risk
factors, and healthy controls).
To clarify the critical cutoff value for NR2 peptide concentra-
tions, four distinct control groups were studied: healthy volunteers,
individuals with controlled vascular risk factors, individuals
presenting with acute stroke-like symptoms who did not have a
stroke and patients with acute stroke (TIA). The analysis of NR2
peptide value variance in patients with acute IS and control group
(healthy individuals and persons with controlled vascular risk
factors) yielded in statistically significant (P,0.0001) increase of
NR2 peptide values in acute IS.
Data analyses yielded two cutoff values, 0.5 ug/L and 1.0 ug/L.
Some healthy individuals showed increase in their NR2 peptide of
1.10–1.15 ug/mL. This may be due to unreported chronic
inflammatory disease. Autoimmune disorders (lupus erythemato-
sus, rheumatoid arthritis) neurovasculitis, and renal disorders may
have elevated NR2 peptide in certain cases and because NMDA
receptors located on the surface of microvessels, they should
respond to inflammation [18]. It is well known that in some cases
these disorders have a high risk for stroke. The case of probable
neurovasculities resulted in ischemic stroke has been described
recently in case report study (see File S1) [17]. Also individuals
with vascular risk factors such as diabetes and hypertension
showed elevated NR2 peptide levels (up to 1.54 ug/L) and NR2
antibodies [17,19] that may indicate microcirculatory dysfunction
in this group.
We also demonstrated the statistically significant increase in
NR2 peptide in acute IS compared to non-stroke (P,0.0001). In 3
Table 1. Characteristics of the study population.
Feature IS n=101 Non-Stroke n=91 Controls
Healthy n=52
Controlled vascular risk
factors, n =48
Median age (range in years) 62.0(26–95) 61.0(24–95) 59.0(29–92) 60(28–80)
Male gender (%) 54(53.5) 52(52.5) 28(53.8) 26(54.1)
Median time of symptom onset 8.2 9.0 - -
Number presenting
0–12 h 33 30 - -
12–24 h 17 20 - -
24–72 h 51 41 - -
Vascular risk factors/n (%)
Diabetes mellitus 23/101(23) 24/91(26) - 4/48(8)
Hypertension 49/101(49) 40/91(44) - 27/48(56)
Heart disease 21/101(21) 19/91(21) - 0
Past history of stroke/n (%) 62/101(61) 57/91(63) - -
Risk factors for stroke mimic/n (%)
Migraine - 2/91(2) - -
Seizures 1/101(1) 3/91(3) - -
Meningitis - 15/91(16) - -
NIHSS
Mean 7.0 4.0 - -
median 5.3 3.0 - -
Number with CT/MRI(%) 101(100) 94(95) - -
doi:10.1371/journal.pone.0042362.t001
NR2 Peptide Assay for Acute Ischemic Stroke
PLoS ONE | www.plosone.org 4 July 2012 | Volume 7 | Issue 7 | e42362
patients who presented with acute stroke symptoms but had no
stroke the NR2 peptide concentrations were above the 1.0 ug/L
threshold. One of these patients had migraine (6.84 ug/L), one
suffered seizures (1.1 ug/L) and had prior TIA and stroke (.1
year). The third one was diagnosed with meningitis (1.3 ug/L).
This is a potential limitation of the use of the assay and therefore
should be always used in conjunction with clinical assessment and
followed up by imaging studies.
Figure 2. Distribution of plasma NR2 peptide concentrations in (A) healthy controls (n=52), persons with controlled vascular risk
factors (n =48), non-stroke (n=99) and acute ischemic stroke (n=101). Distribution of NR2 peptide in plasma of patients with acute IS
depending on time of symptom onset: n = 10 at 1–3 h, n = 8 at 3–6 h, n = 15 at 6–12 h, n = 17 at 12–24 h, and n=51 at 24–72 h (B). Correlation of
NR2 peptide concentrations with new cortical lesion (C). ROC curves for plasma NR2 peptide depended comparison group (D). Areas under the each
curve are 0.930 calculated for the biomarker potential to distinguish acute IS vs certain control group, 0.914 for acute IS vs non-stroke, and 0.920 for
acute IS vs combined control and non-stroke groups.
doi:10.1371/journal.pone.0042362.g002
Table 2. Operating characteristics of different cutoff points for NR2 peptide concentrations in all study groups.
Parameter NR2 peptide test performance at respective cutoff values
0.5 ug/L 1.0 ug/L
Sensitivity, % (95% CI) 98.0 (93.0 to 99.8) 92.1 (85.0 to 96.5)
Specificity, % (95% CI) 71.9 (65.1 to 78.0) 96.5 (92.9 to 98.6)
Positive predictive value, % (95% CI) 63.9 (55.8 to 71.4) 93.0 (86.1 to 97.1)
Negative predictive value, % (95% CI) 98.6 (95.1 to 99.8) 96.0 (92.3 to 98.3)
Positive likelihood ratio (95% CI) 3.48 (2.78 to 4.36) 26.2 (12.62 to 54.31)
Negative likelihood ratio (95% CI) 0.03 (0.01 to 0.11) 0.08 (0.04 to 0.16)
doi:10.1371/journal.pone.0042362.t002
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PLoS ONE | www.plosone.org 5 July 2012 | Volume 7 | Issue 7 | e42362
While a moderate correlation of NR2 peptide values and new
ischemic cortical lesion with stroke volumes below 200 mL was
observed, several patients with acute IS (new cortical lesion of 5–
50 mL) had NR2 peptide concentrations below optimal cut off of
1.0 ug/L. This could be attributed to a number of reasons: (i)
blood sample was drawn from patient beyond 24 h of symptom
onset when biomarker values are already diminishing, (ii) NR2
biomarker might be sensitive to oligemia in the ischemic
penumbra and probably, do not respond to necrosis in ischemic
core [20], (iii) NR2 peptide values may depend on origin of stroke
(thrombotic, embolic, occlusion of small blood vessels or micro-
vessels), and (iv) it might be a false negative result. Further
investigations of the biomarker in hyper-acute and acute stroke
implying advanced DWI/MRI (3T and higher resolution) might
clarify the nature of low NR2 peptide values.
Measurement of the NR2 peptide with a threshold of 1.0 ug/L
for patients with symptoms suspected of ischemic stroke presenting
within 72 h of symptom onset, may have a potential clinical
indication: to assist in the emergent diagnosis of ischemic stroke vs
non-stroke prior other diagnostic procedures will be assigned. This
premise is supported by the predictive value of the test for
recognizing individuals with acute cortical and subcortical IS (93%
at 1.0 ug/L cutoff; likelihood ratio, 26.2) and preliminary assessed
correlation of biomarker with cortical lesions where NMDA
receptors are located. Conversely, the test could be used for ruling
out individuals without acute IS. If the test at a cutoff point of
1.0 ug/L were negative, the probability in a posttest for IS would
be low (about 4%). The latter could be an approach to speed up
ruling out non-stroke within first hours after the onset, when NR2
peptide values were the highest.
In this study biomarker was measured in a single blood draw
taken on admission from all participants. It was not intended to
examine the effect of medication on the NR2 peptide levels.
However, interference of some medication (thrombolytics and
anticoagulants) with the biomarker values has been registered and
should be explored additionally.
Obtained data suggest that the NR2 peptide could serve as a
brain specific biomarker for assessment of acute ischemic stroke.
Combined with clinical assessment and neuroimaging it has a
potential to differentiate IS from non-stroke in ED. Further clinical
studies of the NR2 peptide could expose other possible clinical
utilities.
Study limitations
Certain conditions such as brain tumors, autoimmune diseases,
or acute CNS infection may result in increased NR2 peptide levels,
resulting in false positive diagnoses. Future investigations analyzing
the NR2 peptide concentration in these patients and comparing
them with brain MRI will help estimate the potential of false
positive NR2 assays. Although these conditions are relatively easy
to differentiate clinically, this potential limitation will require
detailed assessment.
It is possible that the NR2 peptide is not able to detect certain
strokes. Specifically, the detection limit for small strokes or small
noncortical IS is currently unknown. In our preliminary clinical
studies, we could detect small cortical strokes (lesion size: 1–2 mL,
n= 14); however, small lacunar subcortical strokes did not always
result in elevated NR2 peptide levels and may at times go
undetected. The sensitivity of MRI for small infarcts also at times
is limited and a future study needs to compare the positive
predictive values of the NR2 peptide with DWI/MRI and clinical
assessments. Additionally, thus far we have only limited data to
know whether the NR2 peptide becomes elevated within the
hyperacute phase of IS (1–3 h of symptom onset).
A body of MRI-based analyses of lesion size should be
performed simultaneously with biomarker detection to estimate
the preliminary correlation between lesion size and NR2 peptide
levels demonstrated here. There may be a significant time lag
between blood draw and MRI (24–72 h), which could confound
findings. A study of a subpopulation of patients who presented
early after stroke symptom onset (within 3 h) and who had rapid
advanced imaging to gain a first glimpse into the relation between
dynamic changes in brain tissue perfusion, penumbra size, and
their effect on biomarker levels would be needed. This information
may be useful for future studies using the biomarker to assess
stroke risk, outcome, and to help with the selection of acute stroke
interventions.
Stroke is different from a TIA and if group TIA and stroke
together, cutoffs and all results may be affected. Significant
number of TIA patients with symptoms still presented (within 1 h
of onset) should be enrolled in separate investigation and a
statistical analysis should be performed to eliminate all biases.
Multiple group comparisons also raise the awareness with the
attention focused on the strongest differences among all compar-
isons that are made. As more groups are considered, it becomes
more likely that the test may appear to be an improvement over
existing methods in terms of at least one symptom. As the number
of comparisons increases, it becomes more likely that the groups
being compared will appear to differ in terms of at least one
attribute. However a difference between the groups is only
meaningful if it generalizes to an independent sample of data (e.g.
to an independent set of people tested with the same assay).
Supporting Information
File S1 Case report study paper by Weissman JD,
Khunteev GA, Dambinova SA (2012) Biomarkers in acute
stroke. MAG J 3: 20–22.
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